Lupin has launched authorized generic version of PENNSAID (Diclofenac Sodium Topical Solution), 2% w/w of Horizon Pharma Therapeutics. Diclofenac Sodium Topical Solution, 2% w/w (RLD PENNSAID) had estimated annual sales of $509 million in the U.S.
Earlier, the company had launched Rufinamide Tablets USP, 200 mg and 400 mg, to market a generic equivalent of Banzel Tablets, 200 mg and 400 mg, of Eisai.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
